Compare FFBC & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFBC | ICUCW |
|---|---|---|
| Founded | 1863 | N/A |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | N/A |
| IPO Year | N/A | 2021 |
| Metric | FFBC | ICUCW |
|---|---|---|
| Price | $25.76 | $0.01 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $28.83 | N/A |
| AVG Volume (30 Days) | ★ 485.6K | N/A |
| Earning Date | 01-22-2026 | N/A |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $815,886,000.00 | N/A |
| Revenue This Year | $23.41 | N/A |
| Revenue Next Year | $19.39 | N/A |
| P/E Ratio | $9.53 | ★ N/A |
| Revenue Growth | ★ 7.05 | N/A |
| 52 Week Low | $21.10 | N/A |
| 52 Week High | $30.36 | N/A |
| Indicator | FFBC | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 40.14 |
| Support Level | $24.48 | $0.01 |
| Resistance Level | $25.44 | $0.01 |
| Average True Range (ATR) | 0.55 | 0.00 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 94.66 | 35.98 |
First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and noninterest-bearing accounts, time deposits and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.